Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion ...

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Shares in Roche rallied in Europe, while ...

Eli Lilly is set to launch its popular weight-loss drug in emerging markets, including India, Brazil, and Mexico, by mid-2025 ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.